Calcipotriene/Betamethasone Dipropionate Cream vs Calcipotriol/Betamethasone Dipropionate Gel

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: Vitamin D receptor + Glucocorticoid receptor · full Psoriasis pipeline

Calcipotriene/Betamethasone Dipropionate Cream · Wynzora

Marketed by MC2 Therapeutics

Approved in Psoriasissmall molecule
Partial signal

NCT03308799 · Phase 3 · completed

This randomized, investigator-blind Phase 3 trial gave calcipotriene/betamethasone dipropionate cream (MC2-01, Wynzora), CAL/BDP topical suspension or cream vehicle once daily for 8 weeks to 796 patients with psoriasis. The primary endpoint was PGA treatment success at week 8. The cream was significantly better than both the topical suspension (37.4% vs 22.8%) and the vehicle (3.7%), each P<0.0001, so the primary was met. Source: the peer-reviewed paper (Stein Gold et al., J Drugs Dermatol 2021), which cites this NCT number.

Reported efficacy

Percentage Change in mPASI (Modified Psoriasis Area and Severity Index) Score (8 Weeks): Percentage Change in mPASI (Modified Psoriasis Area and Severity Index) Score (8 Weeks): MC2-01 Cream -67.5% (Standard Error 20.8) vs Cal/BDP Combination -63.5% (Standard Error 22.2) vs Vehicle -11.7% (Standard Error 21.9) (unclear)

Result source: NCT03802344

Calcipotriol/Betamethasone Dipropionate Gel · Taclonex

Marketed by LEO Pharma

Approved in Psoriasissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCalcipotriene/​Betamethasone Dipropionate CreamCalcipotriol/​Betamethasone Dipropionate Gel
PASI 75—Not reported—Not posted · NCT00216827
PASI 90—Not reported—Not posted · NCT00216827
PASI 100—Not reported—Not posted · NCT00216827
sPGA 0/1—Not reported—Not posted · NCT00216827
DLQI, change—Not reported—Not posted · NCT00216827

PASI 75

Calcipotriene/​Betamethasone Dipropionate Cream
—Not reported
Calcipotriol/​Betamethasone Dipropionate Gel
—Not posted · NCT00216827

PASI 90

Calcipotriene/​Betamethasone Dipropionate Cream
—Not reported
Calcipotriol/​Betamethasone Dipropionate Gel
—Not posted · NCT00216827

PASI 100

Calcipotriene/​Betamethasone Dipropionate Cream
—Not reported
Calcipotriol/​Betamethasone Dipropionate Gel
—Not posted · NCT00216827

sPGA 0/1

Calcipotriene/​Betamethasone Dipropionate Cream
—Not reported
Calcipotriol/​Betamethasone Dipropionate Gel
—Not posted · NCT00216827

DLQI, change

Calcipotriene/​Betamethasone Dipropionate Cream
—Not reported
Calcipotriol/​Betamethasone Dipropionate Gel
—Not posted · NCT00216827
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Calcipotriol/Betamethasone Dipropionate Gel: no structured comparison results are available for Psoriasis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Calcipotriene/Betamethasone Dipropionate Cream: 3 of 4 rows · Calcipotriol/Betamethasone Dipropionate Gel: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCalcipotriene/​Betamethasone Dipropionate Cream
Dropout rate
8.3%
NCT03308799 · Phase 3 · Psoriasis · phase 3
show 1 more result
3.8%
NCT03802344 · Phase 3 · monotherapy · Psoriasis · phase 3
Discontinued due to AEs
—
NCT03308799 · Phase 3 · Psoriasis · phase 3
show 1 more result
—
NCT03802344 · Phase 3 · monotherapy · Psoriasis · phase 3
Serious AEs
3.3%
NCT03308799 · Phase 3 · Psoriasis · phase 3
show 1 more result
0.5%
NCT03802344 · Phase 3 · monotherapy · Psoriasis · phase 3
Most frequent reported AEs
nasopharyngitis 4.7% (placebo 1.5%)
NCT03802344 · Phase 3 · monotherapy · Psoriasis · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Calcipotriene/Betamethasone Dipropionate Cream

PGA 2-point Improvement 24% (n=279) vs 4.5% (n=88) placebo @ 8wk
event count · % of participants
NCT03308799 · Phase 3 · Psoriasis · phase 3 · converted to % from 67 Count of participants as posted
PASI 52.3% (n=279) vs 25.7% (n=88) placebo @ 8wk
percent change · % of baseline
NCT03308799 · Phase 3 · Psoriasis · phase 3
show 1 more result
-67.5% (n=213) vs -11.7% (n=68) placebo @ 8wk
NCT03802344 · Phase 3 · monotherapy · Psoriasis · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Calcipotriene/Betamethasone Dipropionate Cream's landscape · Calcipotriol/Betamethasone Dipropionate Gel's landscape